Cost Plus Drugs Adds Starjemza to Portfolio
Mark Cuban Cost Plus Drug Company announced the inclusion of Starjemza, a biosimilar medication, in its expanding lineup of affordable prescription drugs. This update furthers the company's goal to disrupt traditional drug pricing by increasing patient access to specialty medicines at much lower costs.
Addressing Specialty Medicine Costs
Specialty medicines represent a small portion of prescriptions but account for a large share of U.S. drug spending, often making them unaffordable for many patients. Cost Plus Drugs challenges this by applying a transparent cost-plus pricing model to specialty care.
Pricing Details for Starjemza
Starjemza will be available starting at $345 per quarter (plus shipping) for the 90 mg/mL pre-filled syringe (PFS). Other options, including 45 mg/mL and 130 mg/mL PFS, will be priced clearly according to the company’s cost-plus approach.
Transparent Pricing Model
Unlike traditional prices that use complex rebate systems, Cost Plus Drugs breaks down each cost component, including acquisition cost, a fixed markup, and a pharmacy fee.
“Our goal has always been to ensure that no one is priced out of the medication they need,” said Mark Cuban, co-founder of Cost Plus Drugs.
Author’s summary: Cost Plus Drugs expands its affordable offerings with Starjemza, applying transparent pricing to specialty medications and aiming to make essential drugs accessible for all.